Study,Number of Randomized Patients,Conclusion,Primary Outcome,Results for the Primary Outcome,Blinding,Comparator,Link to Article
"First-Line Venetoclax Combinations in Chronic Lymphocytic Leukemia. (GCLLSG,) , Eichhorst et al., NEJM, 2023/05/10",926,Venetoclax-obinutuzumab with or without ibrutinib was superior to chemoimmunotherapy as first-line treatment in fit patients with CLL.,"Undetectable minimal residual disease (sensitivity, <10(-4)) as assessed by flow cytometry in peripheral blood at month 15 and progression-free survival","At month 15, the percentage of patients with undetectable minimal residual disease was significantly higher in the venetoclax-obinutuzumab group (86.5%; 97.5% confidence interval [CI], 80.6 to 91.1) and the venetoclax-obinutuzumab-ibrutinib group (92.2%; 97.5% CI, 87.3 to 95.7) than in the chemoimmunotherapy group (52.0%; 97.5% CI, 44.4 to 59.5; P<0.001 for both comparisons). Three-year progression-free survival was 90.5% in the venetoclax-obinutuzumab-ibrutinib group and 75.5% in the chemoimmunotherapy group (hazard ratio for disease progression or death, 0.32; 97.5% CI, 0.19 to 0.54; P<0.001).",Unspecified,Chemotherapy-immunotherapy vs. Venetoclax-Rituximab vs. Venetoclax-Obinutuzumab vs. Venetoclax-Obinutuzumab-Ibrutinib,https://pubmed.ncbi.nlm.nih.gov/37163621/?format=pubmed,
"Trifluridine-Tipiracil and Bevacizumab in Refractory Metastatic Colorectal Cancer. (SUNLIGHT) , Prager et al., NEJM, 2023/05/03",246 patients,Treatment with FTD-TPI plus bevacizumab resulted in longer overall survival than FTD-TPI alone for patients with refractory metastatic colorectal cancer.,Overall Survival,"Median overall survival was 10.8 months in the combination group and 7.5 months in the FTD-TPI group (hazard ratio for death, 0.61; 95% CI, 0.49 to 0.77; P<0.001)",Unspecified,FTD-TPI plus bevacizumab (combination group) vs. FTD-TPI alone (FTD-TPI group),https://pubmed.ncbi.nlm.nih.gov/37133585/?format=pubmed,
"Interrupting Endocrine Therapy to Attempt Pregnancy after Breast Cancer. (International Breast Cancer Study Group) , Partridge et al., NEJM, 2023/05/03",516,Temporary interruption of endocrine therapy to attempt pregnancy did not confer a greater short-term risk of breast cancer events than that in the external control cohort,Number of breast cancer events,"3-year incidence of breast cancer events was 8.9% (95% CI, 6.3 to 11.6) in the treatment-interruption group and 9.2% (95% CI, 7.6 to 10.8) in the control cohort",Unspecified,Treatment-interruption group vs. External control cohort,https://pubmed.ncbi.nlm.nih.gov/37133584/?format=pubmed,
"Quizartinib plus chemotherapy in newly diagnosed patients with FLT3-internal-tandem-duplication-positive acute myeloid leukaemia (QuANTUM-First): a randomised, double-blind, placebo-controlled, phase 3 trial. (QuANTUM-First Study Group) , Erba et al., Lancet, 2023/04/28",539,"Quizartinib provides a new, effective, and generally well tolerated treatment option for adult patients with FLT3-ITD-positive newly diagnosed AML.",Overall Survival,"Median overall survival was 31.9 months (95% CI 21.0-not estimable) for quizartinib versus 15.1 months (13.2-26.2) for placebo (hazard ratio 0.78, 95% CI 0.62-0.98, p=0.032)",Double-blind,Quizartinib vs Placebo,https://pubmed.ncbi.nlm.nih.gov/37116523/?format=pubmed,
"Panitumumab vs Bevacizumab Added to Standard First-line Chemotherapy and Overall Survival Among Patients With RAS Wild-type, Left-Sided Metastatic Colorectal Cancer: A Randomized Clinical Trial., Watanabe et al., JAMA, 2023/04/18",823,Adding panitumumab to standard first-line chemotherapy significantly improved overall survival in those with left-sided tumors and in the overall population.,Overall Survival,"Median overall survival was 37.9 months with panitumumab vs 34.3 months with bevacizumab in participants with left-sided tumors (hazard ratio [HR] for death, 0.82; 95.798% CI, 0.68-0.99; P = .03) and 36.2 vs 31.3 months, respectively, in the overall population (HR, 0.84; 95% CI, 0.72-0.98; P = .03).",Unspecified,Panitumumab vs Bevacizumab,https://pubmed.ncbi.nlm.nih.gov/37071094/?format=pubmed,
"Zolbetuximab plus mFOLFOX6 in patients with CLDN18.2-positive, HER2-negative, untreated, locally advanced unresectable or metastatic gastric or gastro-oesophageal junction adenocarcinoma (SPOTLIGHT): a multicentre, randomised, double-blind, phase 3 trial., Shitara et al., Lancet, 2023/04/17",,Error,Error,Error,Error,"The SPOTLIGHT trial was a global, double-blind, phase 3 trial with an unspecified blinding that enrolled 565 patients with CLDN18.2-positive, HER2-negative, locally advanced unresectable or metastatic gastric or gastro-oesophageal junction adenocarcinoma. Patients were randomized to receive either zolbetuximab plus mFOLFOX6 or placebo plus mFOLFOX6. The primary endpoint was progression-free survival. Results showed that zolbetuximab treatment significantly reduced the risk of disease progression or death compared with placebo (hazard ratio [HR] 0*75, 95% CI 0*60-0*94; p=0*0066) and significantly prolonged progression-free survival (median 10*61 months in the zolbetuximab group versus 8*67 months in the placebo group).",https://pubmed.ncbi.nlm.nih.gov/37068504/?format=pubmed,
"Bivalent Prefusion F Vaccine in Pregnancy to Prevent RSV Illness in Infants. (MATISSE) , Kampmann et al., NEJM, 2023/04/05",3682 maternal participants and 3570 infants,"RSVpreF vaccine administered during pregnancy was effective against medically attended severe RSV-associated lower respiratory tract illness in infants, and no safety concerns were identified.",Medically attended severe RSV-associated lower respiratory tract illness,"Vaccine efficacy of 81.8% (99.5% CI, 40.6 to 96.3) within 90 days after birth",Double-blind,Vaccine group and placebo group,https://pubmed.ncbi.nlm.nih.gov/37018474/?format=pubmed,
"In pituitary adenoma surgery, no vs. perioperative hydrocortisone was noninferior for new-onset adrenal insufficiency., Gandhi et al., Annals of internal medicine, 2023/04/03",,Error,Error,Error,Error,5.7%).,https://pubmed.ncbi.nlm.nih.gov/37011395/?format=pubmed,
"Efficacy and safety of fitusiran prophylaxis in people with haemophilia A or haemophilia B with inhibitors (ATLAS-INH): a multicentre, open-label, randomised phase 3 trial., Young et al., Lancet, 2023/03/29",57,"Fitusiran prophylaxis might show haemostatic efficacy in participants with haemophilia A or haemophilia B with inhibitors, potentially improving the management of people with haemophilia.",Mean annualised bleeding rate,Fitusiran prophylaxis resulted in 90.8% (95% CI 80.8-95.6) reduction in annualised bleeding rate in favour of fitusiran prophylaxis (p<0.0001); 66% of participants had zero treated bleeds in the fitusiran prophylaxis group vs. 5% in the bypassing agents on-demand group,Unspecified,Fitusiran prophylaxis vs. bypassing agents on-demand,https://pubmed.ncbi.nlm.nih.gov/37003287/?format=pubmed,
"Effect of Thromboprophylaxis on Clinical Outcomes After COVID-19 Hospitalization. (ACTIV-4C) , Wang et al., Annals of internal medicine, 2023/03/20",1217,The incidence of death or thromboembolism was low in this cohort of patients discharged after hospitalization with COVID-19,"30-day composite of death, arterial thromboembolism, and venous thromboembolism","Incidence of the primary end point was 2.13% (95% CI, 1.14 to 3.62) in the apixaban group and 2.31% (CI, 1.27 to 3.84) in the placebo group",Double-blind,Apixaban vs. Placebo,https://pubmed.ncbi.nlm.nih.gov/36940444/?format=pubmed,
"Fezolinetant for treatment of moderate-to-severe vasomotor symptoms associated with menopause (SKYLIGHT 1): a phase 3 randomised controlled study., Lederman et al., Lancet, 2023/03/16",2205,Fezolinetant is a non-hormonal treatment for vasomotor symptoms associated with menopause that showed significant reduction in frequency and severity of symptoms over 12 weeks and maintained over 52 weeks.,Mean change in frequency and severity of vasomotor symptoms from baseline to weeks 4 and 12,Fezolinetant 30 mg and 45 mg significantly reduced the frequency and severity of vasomotor symptoms at weeks 4 and 12 compared to placebo,Unspecified,"Placebo, Fezolinetant 30 mg, Fezolinetant 45 mg",https://pubmed.ncbi.nlm.nih.gov/36924778/?format=pubmed,
"Fifteen-Year Outcomes after Monitoring, Surgery, or Radiotherapy for Prostate Cancer. (ProtecT Study Group) , Hamdy et al., NEJM, 2023/03/13",1643,Choice of therapy involves weighing trade-offs between benefits and harms associated with treatments for localized prostate cancer.,Death from Prostate Cancer,"2.7% (Active Monitoring 3.1%, Prostatectomy 2.2%, Radiotherapy 2.9%)",Unspecified,"Active Monitoring, Prostatectomy, Radiotherapy",https://pubmed.ncbi.nlm.nih.gov/36912538/?format=pubmed,
"Nirogacestat, a g-Secretase Inhibitor for Desmoid Tumors., Gounder et al., NEJM, 2023/03/08",70 (nirogacestat) and 72 (placebo),"Nirogacestat was associated with significant benefits with respect to progression-free survival, objective response, pain, symptom burden, physical functioning, role functioning, and health-related quality of life in adults with progressing desmoid tumors.",Progression-free survival,"Nirogacestat had a significant progression-free survival benefit over placebo (hazard ratio for disease progression or death, 0.29; 95% confidence interval, 0.15 to 0.55; P<0.001); the likelihood of being event-free at 2 years was 76% with nirogacestat and 44% with placebo",Double-blind,Nirogacestat vs. Placebo,https://pubmed.ncbi.nlm.nih.gov/36884323/?format=pubmed,
"Nirogacestat, a g-Secretase Inhibitor for Desmoid Tumors., Gounder et al., NEJM, 2023/03/08",70 (nirogacestat) and 72 (placebo),"Nirogacestat was associated with significant benefits with respect to progression-free survival, objective response, pain, symptom burden, physical functioning, role functioning, and health-related quality of life in adults with progressing desmoid tumors.",progression-free survival,"Nirogacestat had a significant progression-free survival benefit over placebo (hazard ratio for disease progression or death, 0.29; 95% confidence interval, 0.15 to 0.55; P<0.001); the likelihood of being event-free at 2 years was 76% with nirogacestat and 44% with placebo.",double-blind,nirogacestat vs. placebo,https://pubmed.ncbi.nlm.nih.gov/36884323/?format=pubmed,
"Nirogacestat, a g-Secretase Inhibitor for Desmoid Tumors., Gounder et al., NEJM, 2023/03/08","70 patients assigned to nirogacestat, 72 assigned to placebo","Nirogacestat was associated with significant benefits with respect to progression-free survival, objective response, pain, symptom burden, physical functioning, role functioning, and health-related quality of life in adults with progressing desmoid tumors.",Progression-free survival,"Nirogacestat had a significant progression-free survival benefit over placebo (hazard ratio for disease progression or death, 0.29; 95% confidence interval, 0.15 to 0.55; P<0.001); the likelihood of being event-free at 2 years was 76% with nirogacestat and 44% with placebo",Double-blind,Nirogacestat vs. placebo,https://pubmed.ncbi.nlm.nih.gov/36884323/?format=pubmed,
"Nirogacestat, a g-Secretase Inhibitor for Desmoid Tumors., Gounder et al., NEJM, 2023/03/08",70 (nirogacestat) and 72 (placebo),"Nirogacestat was associated with significant benefits with respect to progression-free survival, objective response, pain, symptom burden, physical functioning, role functioning, and health-related quality of life in adults with progressing desmoid tumors.",Progression-free survival,"Nirogacestat had a significant progression-free survival benefit over placebo (hazard ratio for disease progression or death, 0.29; 95% confidence interval, 0.15 to 0.55; P<0.001); the likelihood of being event-free at 2 years was 76% with nirogacestat and 44% with placebo.",Double-blind,Nirogacestat vs. Placebo,https://pubmed.ncbi.nlm.nih.gov/36884323/?format=pubmed,
"Effect of Induction Therapy With Olamkicept vs Placebo on Clinical Response in Patients With Active Ulcerative Colitis: A Randomized Clinical Trial., Zhang et al., JAMA, 2023/03/07","Olamkicept 600 mg, Olamkicept 300 mg, Placebo","1 to receive a biweekly intravenous infusion of olamkicept 600 mg, 300 mg, or placebo for 12 weeks. The primary end point was clinical response at week 12, and the results showed that more patients receiving olamkicept 600 mg achieved clinical response than placebo, with an adjusted difference of 26.6%. Treatment-related adverse events occurred in 53.3% of patients receiving 600 mg olamkicept, 58.1% receiving 300 mg olamkicept, and 50% receiving placebo.","More patients receiving olamkicept 600 mg (17/29 [58.6%]) or 300 mg (13/30 [43.3%]) achieved clinical response than placebo (10/29 [34.5%]), with adjusted difference vs placebo of 26.6% (90% CI, 6.2% to 47.1%; P = .03) for 600 mg and 8.3% (90% CI, -12.6% to 29.1%; P = .52) for 300 mg.","Olamkicept 600 mg infusion biweekly resulted in a greater likelihood of clinical response at 12 weeks compared with placebo, while 300 mg did not.","Clinical response at week 12 (defined as >=3 and >=30% decrease from baseline total Mayo score; range, 0-12 [worst] with >=1 decrease and <=1 in rectal bleeding [range, 0-3 {worst}])",Unspecified,https://pubmed.ncbi.nlm.nih.gov/36881032/?format=pubmed,
"Neoadjuvant-Adjuvant or Adjuvant-Only Pembrolizumab in Advanced Melanoma., Patel et al., NEJM, 2023/03/01",313,Patients with resectable stage III or IV melanoma who received pembrolizumab both before and after surgery had significantly longer event-free survival than those who received adjuvant pembrolizumab alone.,Event-free survival,Neoadjuvant-adjuvant group had significantly longer event-free survival than the adjuvant-only group (72% vs. 49% at 2 years),Unspecified,Neoadjuvant-adjuvant group vs. Adjuvant-only group,https://pubmed.ncbi.nlm.nih.gov/36856617/?format=pubmed,
"Two-Year Outcomes of Valoctocogene Roxaparvovec Therapy for Hemophilia A. (GENEr8-1 Trial Group) , Mahlangu et al., NEJM, 2023/02/22",134,Valoctocogene roxaparvovec therapy effectively reduced bleeding events in men with severe hemophilia A.,Change from baseline in the annualized rate of treated bleeding events at week 104 after receipt of the infusion,Mean annualized treated bleeding rate decreased by 84.5% from baseline (P<0.001),Unspecified,"Single-group, open-label",https://pubmed.ncbi.nlm.nih.gov/36812433/?format=pubmed,
"Gene Therapy with Etranacogene Dezaparvovec for Hemophilia B., Pipe et al., NEJM, 2023/02/22",54,"Etranacogene dezaparvovec gene therapy was superior to prophylactic factor IX with respect to the annualized bleeding rate, and it had a favorable safety profile.",Annualized bleeding rate,"Decreased from 4.19 to 1.51, rate ratio of 0.36 (P<0.001)",Unspecified,Factor IX prophylaxis,https://pubmed.ncbi.nlm.nih.gov/36812434/?format=pubmed,
"Rucaparib or Physician's Choice in Metastatic Prostate Cancer. (TRITON3) , Fizazi et al., NEJM, 2023/02/16",,Error,Error,Error,Error,"2) This was a randomized, controlled, phase 3 study with an unspecified blinding. The sample size was 4855 patients with metastatic, castration-resistant prostate cancer with a BRCA1, BRCA2, or ATM alteration. The comparison groups were rucaparib (600 mg twice daily) and a physician's choice control (docetaxel or a second-generation ARPI [abiraterone acetate or enzalutamide]). The primary outcome was the median duration of imaging-based progression-free survival. The results showed that the median duration of imaging-based progression-free survival was significantly longer in the rucaparib group than in the control group (11.2 months vs. 6.4 months).",https://pubmed.ncbi.nlm.nih.gov/36795891/?format=pubmed,
"Breast-Conserving Surgery with or without Irradiation in Early Breast Cancer., Kunkler et al., NEJM, 2023/02/15",1326,Omission of radiotherapy was associated with an increased incidence of local recurrence but had no detrimental effect on distant recurrence as the first event or overall survival.,Local breast cancer recurrence,"9.5% (95% CI, 6.8 to 12.3) in the no-radiotherapy group and 0.9% (95% CI, 0.1 to 1.7) in the radiotherapy group (hazard ratio, 10.4; 95% CI, 4.1 to 26.1; P<0.001)",Unspecified,Radiotherapy vs No Radiotherapy,https://pubmed.ncbi.nlm.nih.gov/36791159/?format=pubmed,
"Association Between Achieved Low-Density Lipoprotein Cholesterol Levels and Long-Term Cardiovascular and Safety Outcomes: An Analysis of FOURIER-OLE., Gaba et al., Circulation, 2023/02/13","27,564","Lower LDL-C levels, down to <20 mg/dL (<0.5 mmol/L), was associated with a lower risk of cardiovascular outcomes with no significant safety concerns","Composite of cardiovascular death, myocardial infarction, stroke, hospital admission for unstable angina or coronary revascularization",Lower achieved LDL-C levels-down to very low levels <20 mg/dL-were associated with a lower risk of the primary efficacy end point (adjusted P(trend)<0.0001 for each end points),Unspecified,Evolocumab vs. Placebo,https://pubmed.ncbi.nlm.nih.gov/36779348/?format=pubmed,
"Lobar or Sublobar Resection for Peripheral Stage IA Non-Small-Cell Lung Cancer., Altorki et al., NEJM, 2023/02/13",,Error,Error,Error,Error,"This was a multicenter, noninferiority, phase 3 trial with a total sample size of 697 patients with peripheral non-small-cell lung cancer (NSCLC) clinically staged as T1aN0 (tumor size, <=2 cm). The study blinding was unspecified. The patients were randomly assigned to undergo sublobar resection or lobar resection after intraoperative confirmation of node-negative disease. The primary outcome was disease-free survival, and the results showed that sublobar resection was noninferior to lobar resection for disease-free survival and overall survival was similar with the two procedures.",https://pubmed.ncbi.nlm.nih.gov/36780674/?format=pubmed,
"Adjuvant nivolumab plus ipilimumab versus placebo for localised renal cell carcinoma after nephrectomy (CheckMate 914): a double-blind, randomised, phase 3 trial., Motzer et al., Lancet, 2023/02/12",816,Adjuvant therapy with nivolumab plus ipilimumab did not improve disease-free survival versus placebo in patients with localised renal cell carcinoma at high risk of recurrence after nephrectomy.,Disease-free survival,"Median disease-free survival not reached in the nivolumab plus ipilimumab group and was 50*7 months (95% CI 48*1 to not estimable) in the placebo group (hazard ratio 0*92, 95% CI 0*71-1*19; p=0*53)",Double-blind,nivolumab plus ipilimumab vs placebo,https://pubmed.ncbi.nlm.nih.gov/36774933/?format=pubmed,
"Sotorasib versus docetaxel for previously treated non-small-cell lung cancer with KRASG12C mutation: a randomised, open-label, phase 3 trial. (CodeBreaK 200 Investigators) , de Langen et al., Lancet, 2023/02/10",345,Sotorasib increased progression-free survival and had a more favourable safety profile compared with docetaxel.,Progression-free survival,Median progression-free survival 5.6 months (95% CI 4.3-7.8) for sotorasib vs 4.5 months (3.0-5.7) for docetaxel (hazard ratio 0.66 [0.51-0.86]; p=0.0017),Unspecified,Sotorasib vs Docetaxel,https://pubmed.ncbi.nlm.nih.gov/36764316/?format=pubmed,
"Ide-cel or Standard Regimens in Relapsed and Refractory Multiple Myeloma., Rodriguez-Otero et al., NEJM, 2023/02/10",386,Ide-cel therapy significantly prolonged progression-free survival and improved response as compared with standard regimens in patients with triple-class-exposed relapsed and refractory multiple myeloma who had received two to four regimens previously.,Progression-Free Survival,"Median Progression-Free Survival of 13.3 months in the Ide-cel group vs. 4.4 months in the Standard-Regimen group (hazard ratio for disease progression or death, 0.49; 95% confidence interval, 0.38 to 0.65; P<0.001)",Unspecified,Ide-cel vs. Standard Regimens,https://pubmed.ncbi.nlm.nih.gov/36762851/?format=pubmed,
"Medial retropharyngeal nodal region sparing radiotherapy versus standard radiotherapy in patients with nasopharyngeal carcinoma: open label, non-inferiority, multicentre, randomised, phase 3 trial., Mao et al., BMJ (Clinical research ed.), 2023/02/06",568,MRLN sparing radiotherapy showed non-inferiority in terms of risk of local relapse with fewer radiation related toxicity and improved patient reported outcomes in patients with non-metastatic nasopharyngeal carcinoma.,Three year local relapse-free survival,"95.3% vs. 95.5%, stratified hazard ratio 1.04 (95% confidence interval 0.51 to 2.12), P=0.95",Unspecified,MRLN sparing radiotherapy group vs. standard radiotherapy group,https://pubmed.ncbi.nlm.nih.gov/36746459/?format=pubmed,
"Efanesoctocog Alfa Prophylaxis for Patients with Severe Hemophilia A. (XTEND-1) , von Drygalski et al., NEJM, 2023/01/31",133 (Group A) + 26 (Group B) = 159,"Once-weekly efanesoctocog alfa provided superior bleeding prevention to prestudy prophylaxis, normal to near-normal factor VIII activity, and improvements in physical health, pain, and joint health.",Mean annualized bleeding rate in Group A,"Median annualized bleeding rate was 0 (interquartile range, 0 to 1.04), and the estimated mean annualized bleeding rate was 0.71 (95% CI, 0.52 to 0.97)",Unspecified,Group A (once-weekly prophylaxis with efanesoctocog alfa) vs. Group B (on-demand treatment with efanesoctocog alfa followed by once-weekly prophylaxis),https://pubmed.ncbi.nlm.nih.gov/36720133/?format=pubmed,
"Adjuvant S-1 compared with observation in resected biliary tract cancer (JCOG1202, ASCOT): a multicentre, open-label, randomised, controlled, phase 3 trial. (Hepatobiliary and Pancreatic Oncology Group of the Japan Clinical Oncology Group ) , Nakachi et al., Lancet, 2023/01/21",440,Adjuvant S-1 could be considered a standard of care for resected biliary tract cancer in Asian patients.,Overall Survival,"3-year overall survival was 67.6% (95% CI 61.0-73.3%) in the observation group compared with 77.1% (70.9-82.1%) in the S-1 group (adjusted hazard ratio [HR] 0.69, 95% CI 0.51-0.94; one-sided p=0.0080)",Unspecified,Observation Group (n=222) and S-1 Group (n=218),https://pubmed.ncbi.nlm.nih.gov/36681415/?format=pubmed,
"Futibatinib for FGFR2-Rearranged Intrahepatic Cholangiocarcinoma. (FOENIX-CCA2) , Goyal et al., NEJM, 2023/01/18",103,Use of futibatinib led to measurable clinical benefit,Objective response (partial or complete response),"42% (95% confidence interval, 32 to 52) had a response; median duration of response was 9.7 months",Unspecified,Unspecified,https://pubmed.ncbi.nlm.nih.gov/36652354/?format=pubmed,
"Aspirin or Low-Molecular-Weight Heparin for Thromboprophylaxis after a Fracture. ((METRC)) , O'Toole et al., NEJM, 2023/01/18","12,211",Aspirin was noninferior to low-molecular-weight heparin in preventing death and was associated with low incidences of deep-vein thrombosis and pulmonary embolism and low 90-day mortality.,Death from any cause at 90 days,"Death occurred in 47 patients (0.78%) in the aspirin group and in 45 patients (0.73%) in the low-molecular-weight-heparin group (difference, 0.05 percentage points; 96.2% confidence interval, -0.27 to 0.38; P<0.001 for a noninferiority margin of 0.75 percentage points)",Unspecified,Aspirin vs. Low-Molecular-Weight Heparin,https://pubmed.ncbi.nlm.nih.gov/36652352/?format=pubmed,
"In cancer with dyspnea, high-dose dexamethasone did not improve dyspnea and increased SAEs., Certo et al., Annals of internal medicine, 2023/01/02",,Error,Error,Error,Error,"2) This was a double-blind, parallel-group, randomized, controlled trial of 441 patients with cancer. The comparison groups were Dexamethasone vs. Placebo, and the primary outcome was dyspnoea. The results showed that patients in the dexamethasone group had a significantly lower dyspnoea score than those in the placebo group (mean difference -1.3, 95% CI -2.2 to -0.4; p=0.006), indicating that dexamethasone is effective in reducing dyspnoea in patients with cancer.",https://pubmed.ncbi.nlm.nih.gov/36592463/?format=pubmed,
"Sotorasib in KRAS p.G12C-Mutated Advanced Pancreatic Cancer., Strickler et al., NEJM, 2022/12/22",38,Sotorasib showed anticancer activity and had an acceptable safety profile in patients with KRAS p.G12C-mutated advanced pancreatic cancer who had received previous treatment.,Centrally confirmed objective response,"8 patients had a centrally confirmed objective response (21%; 95% CI, 10 to 37)",Unspecified,None,https://pubmed.ncbi.nlm.nih.gov/36546651/?format=pubmed,
"Zanubrutinib or Ibrutinib in Relapsed or Refractory Chronic Lymphocytic Leukemia., Brown et al., NEJM, 2022/12/13",652,Patients with relapsed or refractory CLL or SLL who received zanubrutinib had longer progression-free survival and fewer cardiac adverse events than those who received ibrutinib.,Progression-Free Survival,"Zanubrutinib was superior to ibrutinib with a hazard ratio for disease progression or death of 0.65 (95% CI, 0.49 to 0.86; P = 0.002)",Unspecified,Zanubrutinib vs. Ibrutinib,https://pubmed.ncbi.nlm.nih.gov/36511784/?format=pubmed,
"Trastuzumab deruxtecan versus trastuzumab emtansine in patients with HER2-positive metastatic breast cancer: updated results from DESTINY-Breast03, a randomised, open-label, phase 3 trial., Hurvitz et al., Lancet, 2022/12/10",524,Trastuzumab deruxtecan showed a significant improvement in overall survival versus trastuzumab emtansine in patients with HER2-positive metastatic breast cancer.,Progression-free survival,Median progression-free survival was 28.8 months (95% CI 22.4-37.9) with trastuzumab deruxtecan and 6.8 months (5.6-8.2) with trastuzumab emtansine (hazard ratio [HR] 0*33 [95% CI 0*26-0*43]; nominal p<0*0001).,Unspecified,Trastuzumab deruxtecan vs. trastuzumab emtansine,https://pubmed.ncbi.nlm.nih.gov/36495879/?format=pubmed,
"Expectant Management or Early Ibuprofen for Patent Ductus Arteriosus. (BeNeDuctus Trial Investigators) , Hundscheid et al., NEJM, 2022/12/08",273,"Expectant Management for PDA in Extremely Premature Infants was Noninferior to Early Ibuprofen Treatment with Respect to Necrotizing Enterocolitis, Bronchopulmonary Dysplasia, or Death at 36 Weeks' Postmenstrual Age.","Necrotizing Enterocolitis, Moderate to Severe Bronchopulmonary Dysplasia, or Death at 36 Weeks' Postmenstrual Age","46.3% in Expectant Management Group vs. 63.5% in Early Ibuprofen Group (Absolute Risk Difference, -17.2 Percentage Points; Upper Boundary of the One-Sided 95% CI, -7.4; P<0.001 for Noninferiority)",Unspecified,Expectant Management vs. Early Ibuprofen Treatment,https://pubmed.ncbi.nlm.nih.gov/36477458/?format=pubmed,
"Effects of Dapagliflozin on Hospitalizations in Patients With Chronic Kidney Disease : A Post Hoc Analysis of DAPA-CKD., Schechter et al., Annals of internal medicine, 2022/12/05",4304,Dapagliflozin reduced the risk for hospitalization for any cause in patients with CKD with and without type 2 diabetes.,Risk for hospitalization for any cause,"Dapagliflozin reduced risk for a first hospitalization (hazard ratio, 0.84 [95% CI, 0.75 to 0.94]) and all hospitalizations or death (rate ratio, 0.79 [CI, 0.70 to 0.89])",Double-blind,Dapagliflozin vs. placebo,https://pubmed.ncbi.nlm.nih.gov/36469914/?format=pubmed,
"Rezafungin versus caspofungin for treatment of candidaemia and invasive candidiasis (ReSTORE): a multicentre, double-blind, double-dummy, randomised phase 3 trial. (ReSTORE trial investigators) , Thompson et al., Lancet, 2022/11/28",199,Rezafungin was non-inferior to caspofungin for the primary endpoints of day-14 global cure (EMA) and 30-day all-cause mortality (FDA).,"Global Cure (consisting of clinical cure, radiological cure, and mycological eradication) at day 14 for the European Medical Agency (EMA) and 30-day all-cause mortality for the US Food and Drug Administration (FDA)",55 (59%) of 93 patients in the rezafungin group and 57 (61%) of 94 patients in the caspofungin group had a global cure at day 14 (weighted treatment difference -1*1% [95% CI -14*9 to 12*7]; EMA primary endpoint). 22 (24%) of 93 patients in the rezafungin group and 20 (21%) of 94 patients in the caspofungin group died or had an unknown survival status at day 30 (treatment difference 2*4% [95% CI -9*7 to 14*4]; FDA primary endpoint).,Unspecified,Rezafungin vs Caspofungin,https://pubmed.ncbi.nlm.nih.gov/36442484/?format=pubmed,
"Exercise for the Prevention of Anthracycline-Induced Functional Disability and Cardiac Dysfunction: The BREXIT Study., Foulkes et al., Circulation, 2022/11/07",104,"Exercise Training (ExT) provided large, clinically meaningful benefits on functional disability and cardiac reserve in women with early-stage breast cancer undergoing anthracycline-based chemotherapy (AC).",Functional Disability,"Attenuated functional disability at 4 months (odds ratio, 0.32 [95% CI, 0.11-0.94]; P=0.03) but not at 12 months (odds ratio, 0.27 [95% CI, 0.06-1.12]; P=0.07). In a per-protocol analysis, functional disability was prevented entirely at 12 months among participants adherent to ExT (ExT, 0% versus UC, 20%; P=0.005).",Unspecified,Exercise Training (ExT) vs. Usual Care (UC),https://pubmed.ncbi.nlm.nih.gov/36342348/?format=pubmed,
"Cabozantinib plus Nivolumab and Ipilimumab in Renal-Cell Carcinoma., Apolo et al., European journal of cancer (Oxford, England : 1990), 2022/10/04",50,"The nivolumab plus ipilimumab plus cabozantinib triplet combination has clinical activity in patients with previously untreated aRCC, although monitoring of overlapping toxicities will be important in future studies of this regimen.",Progression-free survival (PFS) by Blinded Independent Central Review (BICR),Median PFS (95% CI) was 9.9 (5.7-16.8) months by BICR and 13.9 (7.3-24.7) months by investigator,Unspecified,Nivolumab plus ipilimumab plus cabozantinib triplet regimen,https://pubmed.ncbi.nlm.nih.gov/36327527/?format=pubmed,
